Related Experiment Video

Updated: Aug 14, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin

Lei Huang1, Dongshu Chen, Derek Liu

  • 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

Cancer Research
|November 17, 2005
PubMed

Insights

MUC1 oncoprotein stabilizes beta-catenin by blocking its degradation, promoting cancer cell growth and tumorigenicity. This interaction is crucial for MUC1-driven cancer development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Beta-catenin dysregulation is linked to human malignancies.
  • The MUC1 oncoprotein is overexpressed in most carcinomas and interacts with beta-catenin.

Purpose of the Study:

  • To elucidate the functional significance of the MUC1-beta-catenin interaction.
  • To determine how MUC1 affects beta-catenin levels and stability.

Main Methods:

  • Investigated MUC1's effect on beta-catenin levels in carcinoma cells.
  • Assessed MUC1's impact on glycogen synthase kinase 3beta (GSK3beta)-mediated beta-catenin phosphorylation and degradation.
  • Identified and mutated a serine-rich motif (SRM) in MUC1 for binding studies.
  • Evaluated the functional consequences of disrupting the MUC1-beta-catenin interaction on cell growth and tumorigenicity.

Main Results:

  • MUC1 increases beta-catenin levels in both cytoplasm and nucleus.
  • MUC1 inhibits GSK3beta-mediated phosphorylation and degradation of beta-catenin.
  • A specific serine-rich motif (SRM) in MUC1 mediates beta-catenin binding.
  • Mutating the SRM reduces MUC1-beta-catenin binding and abrogates MUC1's inhibitory effect on beta-catenin degradation.
  • Disruption of the MUC1-beta-catenin interaction attenuates MUC1-induced cell growth and delays tumorigenicity.

Conclusions:

  • MUC1 promotes cancer development by stabilizing beta-catenin through inhibition of its degradation.
  • The MUC1-beta-catenin interaction, mediated by MUC1's SRM, is a key mechanism in MUC1-driven oncogenesis.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...